• Skip to main content
  • Skip to footer

PeDRA

Pediatric Dermatology Research Alliance

  • DONATE
  • Pay 2023 Membership Dues
  • Join PeDRA
  • Login
MENUMENU
  • Contact Us
  • For Patients & Families
        • Patient Support
        • Patient Education
        • Community Spotlight
        • Play Eczema Counts Now!
        • Patient Advisory Committee
        • Find a Pediatric Dermatologist (from SPD)
        • Parents, advocates, and patients over the age of 18 with a direct connection or significant interest in childhood skin disease or pediatric dermatology research are encouraged to join the PeDRA network for free as Community Members.

          Apply Now!

  • Education and Events
        • Virtual Education
        • SPD/PeDRA Journal Club
        • PeDRA Podcasts
        • Points of Discussion Podcast
        • Mentorship Program
        • 2023 Annual Conference
        • Dash for Discovery Fun Run/Walk
        • Early Investigator Support
        • Play Eczema Counts Now!
        • Events Calendar
        • Save the Date! The 2023 PeDRA Annual Conference will be held November 9-11, 2023 at the Westin Buckhead Atlanta in Atlanta, GA.

           

           

          Explore our new educational catalog!

  • Research
        • Grants and Fellowships
        • Resources for Researchers
        • Survey Application
        • Study Application
        • Research Areas
        • Publications
        • Now accepting applications for the Emerging Investigator Research Grants Program and Research Fellowships Program.

  • About
        • Mission & Vision
        • Leadership & Staff
        • Annual Reports & Financials
        • News Archive
        • Our Supporters
        • Our Membership
        • Our Committees
        • Getting to Know You
        • 2022 marked PeDRA’s 10th year of pursuing the vision of changing lives and healing children with skin disease through collaboration and discovery. Visit our 10th Anniversary Page to learn more about the origin of PeDRA and the many accomplishments during the first ten years!

  • Member Login

Identifying Dysregulated Immune-Related Gene Networks at the Single-Cell Level in Pediatric Morphea

May 18, 2021 By Katherine Devenport

Fellow

Henry Chen
UT Southwestern Medical Center

Mentor

Heidi Jacobe MD, MSCS
UT Southwestern Medical Center

Overview

Morphea, or localized scleroderma, is an idiopathic disorder of the skin and underlying tissue that produces permanent disability and functional impairment due to joint contracture and soft tissue loss. Notably, pediatric-onset morphea is associated with more severe features compared to adult-onset morphea, such as worsened morbidity and prolonged duration of disease, impairing growth and resulting in disfigurement. Morphea has remitting and relapsing periods of activity, marked by inflammation and fibrosis, and damage which produces atrophy. Activity is characterized by an inflammatory dermal and subcutaneous lymphocytic infiltrate manifesting clinically as erythema and edema. Inflammatory activity often overlaps with a fibrotic phase distinguished by dense collagen deposition with infiltration of inflammatory cells manifesting clinically as hardened, discolored plaques. Fibrosis and resultant atrophy of the skin, soft tissue, and bone result in functional impairment. As with other autoimmune disorders, the predominant driver of long-term morphea damage and disability is thought to be the magnitude and duration of the initial active phase, which likely facilitates subsequent damaging fibrosis. However, the dysregulation of immune and fibrotic pathways at single-cell resolution that contribute to these changes has not been systematically studied. The only widely tested treatment for morphea is a combination of corticosteroids and methotrexate, the use of which is substantially limited by toxicity, particularly in the pediatric population. Therefore, characterization of immune pathway aberrations at the single-cell level is quintessential in the identification of molecular targets for therapeutic development.

Aim 1: Identify dysregulated immune networks in morphea relative to matched healthy control skin.

Aim 2: Utilize identified dysregulated immune networks to determine association with disease trajectory and therapeutic response.

Status

This project was funded through a 2021 PeDRA Research Fellowship Grant.

Filed Under: Connective Tissue & Autoimmune

Footer

  • Our Membership
  • For Patients
  • For Researchers
  • Governance Policies
  • Financial Conflict of Interest Policy
  • Jobs at PeDRA
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
Sign up to receive emails from PeDRA
Join PeDRA
Donate

Copyright © 2023 · Pediatric Dermatology Research Alliance (PeDRA) · All Rights Reserved. · Privacy Policy